BioCentury | Jul 8, 2020
Finance

VarmX attracts investor syndicate with financial reserves to support coagulation company beyond €32M series B

Investors in VarmX’s €32 million ($36.1 million) series B round brought together a deep-pocketed syndicate designed to support the Netherlands-based coagulation play through registrational studies for its lead program. INKEF Capital and Ysios Capital co-led...
BC Week In Review | Apr 20, 2018
Company News

BMS, JNJ in deal for Factor XIa inhibitor

Bristol-Myers Squibb Co. (NYSE:BMY) and the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) partnered to develop and commercialize Factor XIa inhibitors, including BMS-986177. BMS will receive an undisclosed upfront payment and is eligible...
BC Extra | Apr 16, 2018
Company News

BMS, JNJ in deal for Factor XIa inhibitor

Bristol-Myers Squibb Co. (NYSE:BMY) and the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) partnered to develop and commercialize Factor XIa inhibitors, including BMS-986177. BMS will receive an undisclosed upfront payment and is eligible...
Items per page:
1 - 3 of 3